← back to search

Robert J. Kreitman

National Cancer Institute · US
Area of research
Immunology · Genetics
Research interest
Research interests include Toxin Mechanisms and Immunotoxins, Chronic Lymphocytic Leukemia Research, Transgenic Plants and Applications, and Monoclonal and Polyclonal Antibodies Research.
h-index
70
citations
17,131
works
347
NIH funding
primary concept
Medicine
email

Recent publications

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
Nature Medicine 2023cited by 287position: middledoi
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study
Annals of Oncology 2022cited by 334position: middledoi
Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries
Nature Genetics 2022cited by 136position: middledoi
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial
Journal of Hematology & Oncology 2021cited by 85position: middledoi
Genetic regulation of <i>OAS1</i> nonsense-mediated decay underlies association with risk of severe COVID-19
medRxiv 2021cited by 12position: middledoi
Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL
Blood 2021cited by 1position: middledoi
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Leukemia 2018cited by 245position: firstdoi
Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up
Blood 2018cited by 70position: firstdoi
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
Blood 2016cited by 285position: middledoi
Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia
Journal of Clinical Oncology 2012cited by 296position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Ira Pastan · Center for Cancer Research3 papers (2012–2021)Tadeusz Robak · Medical University of Lodz3 papers (2012–2021)Vivek Subbiah · International Drug Development2 papers (2022–2023)Wyndham H. Wilson · National Institutes of Health2 papers (2012–2018)Maryalice Stetler‐Stevenson · National Cancer Institute2 papers (2012–2018)David J. FitzGerald · National Institutes of Health2 papers (2012–2018)Jan H.M. Schellens · University of Applied Sciences Utrecht2 papers (2022–2023)Martin S. Tallman · Midwestern University2 papers (2012–2018)Aislyn Boran · Daiichi Sankyo (United States)2 papers (2022–2023)Steven Coutré · Stanford University2 papers (2012–2018)Palanichamy Ilankumaran · Center for Global Development2 papers (2022–2023)Zev A. Wainberg · UCLA Medical Center2 papers (2022–2023)Patrick Y. Wen · Harvard University2 papers (2022–2023)Lionel Karlin · Bristol-Myers Squibb (Switzerland)1 papers (2021–2021)Philipp D. le Coutre · Haukeland University Hospital1 papers (2021–2021)Filip De Vos · Leidsche Rijn Julius Health Centers1 papers (2023–2023)Élena Elez · Comprehensive Cancer Center Vienna1 papers (2023–2023)Robert J. Lechleider · MacroGenics (United States)1 papers (2012–2012) · 1 papers (2021–2021)Jean‐Yves Blay · International Network for Economic, Social and Cultural Rights1 papers (2023–2023)